Cerevance to present Phase 2 solengepras data at Parkinson’s congress

Cerevance said it will present results from its Phase 2 ASCEND trial of solengepras at the 2025 International Congress of Parkinson’s Disease and Movement Disorders, taking place October 5–9 in Honolulu. According to the company, the data include assessments of functional and non-motor outcomes, alongside safety findings. Solengepras is a non-dopaminergic GPR6 receptor inhibitor being […] The post Cerevance to present Phase 2 solengepras data at Parkinson’s congress appeared first on Longevity.Technology.